HC Wainwright Has Optimistic Outlook of INO Q1 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Equities researchers at HC Wainwright lifted their Q1 2025 earnings estimates for Inovio Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.75) per share for the quarter, up from their prior estimate of ($0.78). HC Wainwright has a “Neutral” rating and a $3.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($2.12) EPS.

Several other brokerages also recently issued reports on INO. StockNews.com raised Inovio Pharmaceuticals to a “sell” rating in a report on Friday. Royal Bank of Canada cut their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.20.

Inovio Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ INO opened at $1.92 on Friday. The company has a market capitalization of $50.11 million, a P/E ratio of -0.48 and a beta of 0.92. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The stock has a 50 day moving average of $2.04 and a 200-day moving average of $3.69.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Deep Track Capital LP grew its stake in shares of Inovio Pharmaceuticals by 72.9% in the fourth quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company’s stock valued at $5,708,000 after acquiring an additional 1,314,796 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at about $1,922,000. AIGH Capital Management LLC acquired a new position in shares of Inovio Pharmaceuticals during the 4th quarter worth approximately $1,197,000. Bank of America Corp DE increased its holdings in shares of Inovio Pharmaceuticals by 1,035.2% during the fourth quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company’s stock worth $1,173,000 after purchasing an additional 584,521 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Inovio Pharmaceuticals by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after buying an additional 6,874 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.